Bobbie Douglas, NP
Family · Indianapolis, INNPI 1487047965
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Amgen at 26.3% of the total. 2023 is the largest year on record at $113, 3.0 times the $38 reported in 2021. That places this record below the midpoint for family clinicians in IN, where the typical reported total is $383.
Across 14 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$65
- Kowa Pharmaceuticals America, Inc.$55
- Davol Inc.$37
- Bioventus LLC$33
- Pacira Therapeutics, Inc.$23
- Pfizer$19
- plus $15 from 1 others
What the payments were for
- Food & beverage$247100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 3 | $65 |
| Kowa Pharmaceuticals America, Inc. | 4 | $55 |
| Davol Inc. | 2 | $37 |
| Bioventus LLC | 2 | $33 |
| Pacira Therapeutics, Inc. | 1 | $23 |
| Pfizer | 1 | $19 |
| Masimo Corporation | 1 | $15 |
How this compares
$247 in reported general payments places this provider in the 40th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 106 | $593 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 81 | $485 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 29 | $278 |
| Ondansetron OdtOndansetron | 11 | $130 |
| Cefadroxil | 17 | $106 |
| Tramadol Hcl | 30 | $80 |
| Cephalexin | 19 | $62 |
Paid to pharmacies, not to this prescriber.
Other family in Indianapolis
- Tina SizemoreIndianapolis$888K
- Marla MosesIndianapolis$142K
- Leslye FisherIndianapolis$73K
- Alicia WettrickIndianapolis$72K
- Christine BaltIndianapolis$30K
- Kathryn KennedyIndianapolis$29K
- Andrea RandallIndianapolis$27K
- Deidre ArmsIndianapolis$26K
- Carrie GravesIndianapolis$16K
- Dominique LevequeIndianapolis$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.